Rxcurve
Medicare Part B payment limits Effective October 1 – December 31, 2026 Posted by CMS September 17, 2026
HCPCS J9022 · per 10 MG

Inj, atezolizumab,10 mg

Products billed under this code include Tecentriq.

Payment limit per 10 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.

Products billed under J9022

From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.

ProductLabelerNDCUnits / pkgLimit / pkg
Tecentriq Genentech, Inc. 50242-0917-01 120 $11,624.76
Tecentriq Genentech, Inc. 50242-0918-01 84 $8,137.332

Every quarter

QuarterPayment limitChangeBilling unitDescriptionSource file
4Q26 $96.873 +$0.327 10 MG Inj, atezolizumab,10 mg v1, posted September 17, 2026
3Q26 $96.546 +$2.549 10 MG Inj, atezolizumab,10 mg v1, posted September 15, 2026
2Q26 $93.997 +$0.087 10 MG Inj, atezolizumab,10 mg v1, posted September 15, 2026
1Q26 $93.91 +$2.57 10 MG Inj, atezolizumab,10 mg v1, posted September 15, 2026
4Q25 $91.34 +$0.319 10 MG Inj, atezolizumab,10 mg v1, posted September 8, 2026
3Q25 $91.021 +$1.627 10 MG Inj, atezolizumab,10 mg v1, posted March 10, 2026
2Q25 $89.394 +$1.171 10 MG Inj, atezolizumab,10 mg v1, posted March 10, 2026
1Q25 $88.223 +$1.981 10 MG Inj, atezolizumab,10 mg v1, posted December 19, 2025
4Q24 $86.242 +$0.465 10 MG Inj, atezolizumab,10 mg v1, posted June 11, 2025
3Q24 $85.777 +$1.842 10 MG Inj, atezolizumab,10 mg v1, posted June 11, 2025
2Q24 $83.935 −$1.076 10 MG Inj, atezolizumab,10 mg v1, posted March 11, 2025
1Q24 $85.011 +$2.389 10 MG Inj, atezolizumab,10 mg v1, posted December 19, 2024
4Q23 $82.622 −$0.056 10 MG Inj, atezolizumab,10 mg v1, posted October 10, 2024
3Q23 $82.678 +$1.615 10 MG Inj, atezolizumab,10 mg v1, posted June 5, 2024
2Q23 $81.063 +$0.264 10 MG Inj, atezolizumab,10 mg v1, posted February 23, 2024
1Q23 $80.799 −$1.267 10 MG Inj, atezolizumab,10 mg v1, posted December 6, 2023
4Q22 $82.066 −$0.203 10 MG Inj, atezolizumab,10 mg v1, posted June 22, 2023
3Q22 $82.269 +$3.002 10 MG Inj, atezolizumab,10 mg v1, posted June 9, 2023
2Q22 $79.267 −$0.309 10 MG Inj, atezolizumab,10 mg v1, posted December 14, 2022
1Q22 $79.576 −$0.173 10 MG Inj, atezolizumab,10 mg v1, posted June 8, 2022
4Q21 $79.749 −$0.038 10 MG Inj, atezolizumab,10 mg v1, posted June 2, 2022
3Q21 $79.787 +$1.634 10 MG Inj, atezolizumab,10 mg v1, posted June 2, 2022
2Q21 $78.153 −$0.028 10 MG Inj, atezolizumab,10 mg v1, posted March 1, 2022
1Q21 $78.181 – 10 MG Inj, atezolizumab,10 mg v1, posted December 10, 2021

“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.

CMS source files